OBJECTIVE: To examine the prevalence and prognostic implications of low serum testosterone levels in men with chronic liver disease. DESIGN: We conducted an observational study at a tertiary referral centre. PATIENTS AND MEASUREMENTS: Baseline serum testosterone was measured in 171 men presenting to the Victorian Liver Transplant Unit for liver transplant evaluation. Patients were followed up to liver transplant or death. RESULTS: Sixty-one per cent of men had a low total testosterone level (TT, <10 nm), and 90% of men had a low calculated free testosterone level (cFT, <230 pm). During the available observation time (median 8 months, interquartile range 4-14 months), 56 men (33%) died and 63 (37%) received a liver transplant. Fifty-two (30%) survived without a transplant. Median time to death was 8 months (range 2-13) and to liver transplant was 8 months (4-14). Baseline low TT and cFT levels both (P < 0·0001) predicted mortality. Moreover, in a Cox proportional hazard model, both low total (P = 0·02) and free testosterone (P = 0·007) levels remained predictive of death independently of established prognostic factors, such as the model for end-stage liver disease (MELD) score and serum sodium levels. A decrease in TT by 1 nm and in cFT by 10 pm was associated with an 8% increase in mortality. CONCLUSIONS: Low testosterone levels are common in men with severe liver disease and predict mortality independent of MELD, the standard score used to prioritize the allocation of liver transplants.
OBJECTIVE: To examine the prevalence and prognostic implications of low serum testosterone levels in men with chronic liver disease. DESIGN: We conducted an observational study at a tertiary referral centre. PATIENTS AND MEASUREMENTS: Baseline serum testosterone was measured in 171 men presenting to the Victorian Liver Transplant Unit for liver transplant evaluation. Patients were followed up to liver transplant or death. RESULTS: Sixty-one per cent of men had a low total testosterone level (TT, <10 nm), and 90% of men had a low calculated free testosterone level (cFT, <230 pm). During the available observation time (median 8 months, interquartile range 4-14 months), 56 men (33%) died and 63 (37%) received a liver transplant. Fifty-two (30%) survived without a transplant. Median time to death was 8 months (range 2-13) and to liver transplant was 8 months (4-14). Baseline low TT and cFT levels both (P < 0·0001) predicted mortality. Moreover, in a Cox proportional hazard model, both low total (P = 0·02) and free testosterone (P = 0·007) levels remained predictive of death independently of established prognostic factors, such as the model for end-stage liver disease (MELD) score and serum sodium levels. A decrease in TT by 1 nm and in cFT by 10 pm was associated with an 8% increase in mortality. CONCLUSIONS: Low testosterone levels are common in men with severe liver disease and predict mortality independent of MELD, the standard score used to prioritize the allocation of liver transplants.
Authors: Anees M Dauki; James S Blachly; Esko A Kautto; Sameera Ezzat; Mohamed H Abdel-Rahman; Christopher C Coss Journal: Cancer Res Date: 2019-11-04 Impact factor: 12.701
Authors: Guneet K Jasuja; Shalender Bhasin; Joel I Reisman; Joseph T Hanlon; Donald R Miller; Anthony P Morreale; Leonard M Pogach; Francesca E Cunningham; Angela Park; Dan R Berlowitz; Adam J Rose Journal: J Gen Intern Med Date: 2016-12-19 Impact factor: 5.128
Authors: Penelope Hey; Rudolf Hoermann; Paul Gow; Timothy P Hanrahan; Adam G Testro; Ross Apostolov; Marie Sinclair Journal: World J Transplant Date: 2022-06-18
Authors: A S Cheung; S Baqar; R Sia; R Hoermann; S Iuliano-Burns; T D T Vu; C Chiang; E J Hamilton; E Gianatti; E Seeman; J D Zajac; M Grossmann Journal: Osteoporos Int Date: 2014-05-07 Impact factor: 4.507